x

Blog

Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

blog.png
November 10, 2020 SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race? Explore why upstream KRAS-mutant targets, such as SHP2 and SOS1, may lead to optimized therapeutic combinations for KRAS-mutated cancers. LEARN MORE
November 6, 2020 In Vivo Imaging of Syngeneic Models for Immuno-Oncology Studies Explore how different imaging modalities are used to monitor in vivo immuno-oncology (I/O) studies in syngeneic tumor ... LEARN MORE
October 28, 2020 Thermoneutrality and Preclinical Obesity Models Explore how to improve translatability of preclinical obesity research by using murine thermoneutral conditions. LEARN MORE
October 26, 2020 Applications and Benefits of Engineered Syngeneic Cell Lines Explore the use and main benefits of engineered syngeneic cell lines for investigating drug targets and biological ... LEARN MORE
October 21, 2020 Meet the CrownBio Team: Dr Marrit Putker, Organoid Research Scientist Meet the newest member of CrownBio’s organoid team, Marrit Putker, heading up research at our new Utrecht site. LEARN MORE
October 14, 2020 Evaluating Immunotherapy Mechanism of Action with Immune Cell Lineage-Specific DTR Models Explore how transgenic diphtheria toxin receptor (DTR) preclinical models are used to better understand immunotherapy ... LEARN MORE
October 2, 2020 Next Generation Syngeneic Models: Top 14 Questions Dr Davy Ouyang, CrownBio Vice President of Scientific Research & Innovation answers the most popular questions from his recent syngeneic model webinar, covering the latest research, model developments, and platforms for moving past syngeneics for advanced immuno-oncology studies. LEARN MORE
September 22, 2020 T Cell Dysfunction Assays for In Vitro Screening of Immunomodulatory Drug Candidates Review the latest advances in the recall antigen assay, to provide an optimized system for screening and characterizing ... LEARN MORE
September 17, 2020 HUB Technology: The Only Tumor Organoid Platform Available for Oncology Drug Discovery Explore why adult stem cell (ASC)-derived HUB technology provides the only tumor organoid platform available for ... LEARN MORE
September 15, 2020 Targeting Peroxisome Proliferator-Activated Receptors for NASH Therapy Review the roles of peroxisome proliferator-activated receptor (PPAR) isotypes in managing hepatic and systemic lipid ... LEARN MORE
September 10, 2020 Genome-Wide RNAseq and Array-Based NanoString Transcriptomic Technologies: Which To Use and When? Compare the pros and cons of two widely used transcriptomic technologies - genome-wide RNAseq and array-based NanoString. LEARN MORE
September 8, 2020 Targeting the Fibroblast Growth Factor Axis for NASH Therapy Review the roles of members of the FGF19 subclass of fibroblast growth factor (FGF) hormones in NAFLD and NASH, and the ... LEARN MORE
September 3, 2020 Predicting Clinical Treatment Responses Using HUB Tumor Organoids Explore the power of HUB tumor organoids in predicting clinical response. LEARN MORE
August 27, 2020 Tumor Organoid Applications in Cancer Research Explore tumor organoid applications in cancer research including metastasis modeling, drug screening, understanding ... LEARN MORE
August 20, 2020 Why Choose Tumor Organoids vs Other 3D In Vitro Models for Oncology Drug Development Review the key differences between tumor organoids and other 3D in vitro tumor cell cultures, including spheroids, ... LEARN MORE